FGF21 and obesity due to melanocortin 4 receptor deficiency: FGF21 may represent a promising next-generation preventive and therapeutic strategy that warrants comprehensive testing in human clinical trials of obesity-associated pancreatic cancer, pancreatitis, and other inflammation-related disease states such as NASH and hepatocellular cancer.